AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On May 13, 2020, AXIM® Biotechnologies, Inc. announced that it issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
AXIM BIOTECHNOLOGIES, INC. Exhibit
EX-99.1 2 f8k051320_ex99z1.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1 Press Release Exhibit 99.1 AXIM® Biotechnologies Issues Update Letter to Shareholders SAN DIEGO,…
To view the full exhibit click here
About AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM)
AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson’s disease, Alzheimer’s disease, restless leg syndrome (RLS) and Crohn’s disease.
